What is OncoDNA?
Founded in 2012 and headquartered in Belgium, OncoDNA is dedicated to advancing cancer molecular profiling. The company's core mission is to provide individualized therapy decisions for cancer patients by leveraging cutting-edge diagnostic technologies. This focus on precision medicine positions OncoDNA as a key player in the healthcare technology landscape, aiming to improve patient outcomes through tailored treatment strategies.
How much funding has OncoDNA raised?
OncoDNA has raised a total of $28.6M across 2 funding rounds:
Series A
$8.6M
Series B
$20M
Series A (2016): $8.6M, investors not publicly disclosed
Series B (2020): $20M led by SRIW, Swisscanto Invest, Sofinim, The SFPI-FPIM, Sambrinvest, CPH Bank, Inventures, and Vesalius Biocapital III
Key Investors in OncoDNA
SRIW
Wallonie Entreprendre is the economic and financial tool of Wallonia, dedicated to supporting the entrepreneurial fabric of the region. The organization provides various services including financing, guarantees, and expertise to foster sustainable growth and job creation.
The SFPI-FPIM
SFPI-FPIM, the federal holding and investment company, was created on November 1, 2006, as a result of a merger between the Federal Participation Company and the Federal Investment Company. Its sole shareholder is the federal government.
Sambrinvest
Sambrinvest is a private financial partner based in the Charleroi Métropole, specializing in financing small and medium-sized enterprises (SMEs). With a portfolio of over 300 companies, it offers tailored financing solutions to meet diverse business needs.
What's next for OncoDNA?
The recent major strategic investment signals a new phase of expansion and development for OncoDNA. This capital infusion is expected to fuel further research and development, enhance its profiling capabilities, and potentially broaden its market reach. The company is poised to solidify its role in personalized oncology, driving innovation in cancer diagnostics and treatment planning.
See full OncoDNA company page
